Stroke and traumatic brain injury (TBI) symptoms and signs vary. TBI includes light, noise sensitivity; stroke presents with facial drooping.

Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients living with ocular MG ...

Alexion, AstraZeneca Rare Disease's Ultomiris® (ravulizumab rch) has been listed on the Pharmaceutical Benefits Scheme (PBS) for adults with ...

Findings showed patients treated with efgartigimod alfa–hyaluronidase achieved a statistically significant improvement in MGII PRO ocular scores vs placebo at week 4. Topline data were announced from ...

A case study demonstrates the differential diagnoses that should be considered for patients with symptoms of myasthenia gravis. Intermittent diplopia, transient upper lid ptosis, and eye dysphagia are ...

NEW YORK CITY, New York — Monica Seles, the nine-time Grand Slam champion and International Tennis Hall of Famer, is offering one of her most comprehensive updates yet on how she has been navigating ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. An mRNA‑based CAR T therapy called Descartes‑08 is giving many people with myasthenia gravis ...

Diagnosing myasthenia gravis (MG) has changed the epidemiology of the disease and taken on a new importance for patients and researchers with the emergence of new treatment classes in the last several ...

Myasthenia gravis (MG) or its treatments may lead to urinary symptoms. Studies suggest a link between overactive bladder symptoms and a common MG medication called pyridostigmine. Urinary symptoms in ...

Amid a swell of regulatory successes in the myasthenia gravis arena this decade, Amgen is wading into the fray with a new indication for its monoclonal antibody Uplizna. Thursday, the FDA greenlighted ...

Updates on the efficacy of new and emerging therapies for myasthenia gravis (MG) presented at the American Association of Neuromuscular and Electrodiagnostic Medicine 2025 Annual Meeting are discussed ...

The authors do not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and have disclosed no relevant affiliations beyond their ...